Grace Therapeutics (GRCE) Share-based Compensation (2018 - 2026)

Grace Therapeutics has disclosed Share-based Compensation across 9 years of filings, most recently posting $1.3 million for Q2 2026.

• In Q2 2026, Share-based Compensation changed 0.0% year-over-year to $1.3 million; the TTM figure through Jun 2026 stood at $1.3 million (changed 0.0% YoY), while the FY2026 annual figure was $1.3 million, up 43.91% from the prior year.
• Share-based Compensation came in at $1.3 million for Q2 2026 at Grace Therapeutics, up from $182000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $4.4 million in Q3 2022 to a low of $130000.0 in Q1 2025.
• Average Share-based Compensation over 5 years is $1.4 million, with a median of $927423.0 recorded in 2024.
• Year-over-year, Share-based Compensation soared 391.86% in 2022 and sank 93.7% in 2023.
• Over 5 years, Share-based Compensation stood at $4.4 million in 2022, then plunged by 83.76% to $721793.0 in 2023, then increased by 29.53% to $934923.0 in 2024, then jumped by 44.4% to $1.3 million in 2025, then changed by 0.0% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.3 million in Q2 2026, $182000.0 in Q1 2026, and $1.3 million in Q4 2025.